Universität zu Köln

Broeckelmann, Paul J., von Tresckow, Bastian and Engert, Andreas (2018). Relapsed or refractory classical Hodgkin's lymphoma. Novel therapeutic approaches. Onkologe, 24 (4). S. 322 - 329. NEW YORK: SPRINGER. ISSN 1433-0415

Full text not available from this repository.

Abstract

Classical Hodgkin's lymphoma is highly curable with risk-adapted first-line therapy. Despite a reduction of potential therapy-associated short-term and long-term toxicities, treatment of patients with relapsed or primary refractory disease (r/r HL) remains a clinical challenge. This review summarizes the currently available data regarding safety and efficacy of different therapeutic approaches in r/r HL and provides recommendations for specific clinical situations. Up to 50% of patients eligible for intensified therapies achieve long-term remission after high-dose chemotherapy and autologous stem cell transplantation (ASCT); however, multiple relapsed, refractory, elderly or frail patients until recently had an unfavorable prognosis with mostly palliative therapy. The anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) constitutes a highly effective and tolerable therapeutic option with some durable complete remissions. Accordingly, BV has been approved for r/r HL after ASCT or two prior therapies. More recently, two checkpoint inhibitors, i.aEuroe., the anti-PD1 antibodies nivolumab and pembrolizumab were also investigated in heavily pretreated r/r HL patients. Both drugs were very well tolerated and resulted in high response rates with long-lasting remission. Nivolumab and pembrolizumab were recently approved for r/r HL after prior treatment with BV. In addition, other targeted drugs, such as AFM13, everolimus, panobinostat, mocetinostat as well as agents, such as lenalidomide or bendamustine showed activity in intensively pretreated r/r HL patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-191883
DOI:	10.1007/s00761-018-0336-9
Journal or Publication Title:	Onkologe
Volume:	24
Number:	4
Page Range:	S. 322 - 329
Date:	2018
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; PHASE-II; BRENTUXIMAB VEDOTIN; PROGNOSTIC SCORE; SINGLE-ARM; OPEN-LABEL; TRIAL; MULTICENTER; INTENSITY Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19188